For Hematology/Oncology patients the ExPeCT anti-CD19 (FMC63) CAR T assay provides interventional data which may provide information on the expansion and persistence of the genetically modified T-cells used as therapeutic treatment for specific lymphomas and leukemias (Chimeric Antigen Receptor T-cell therapy or CAR T). Eurofins Viracor has developed and validated a multiplexed quantitative real-time PCR (qPCR) assay targeting FMC63 for the longitudinal monitoring of CD19-directed CAR T-cell therapy.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series 1-5 from ATC 2023 in San Diego. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode of the Eurofins Viracor podcast, our strategic brand manager, Kevin Foth hosts an in-depth discussion with Eurofins Viracor President, Michelle Altrich, and Chief Scientific Officer, Steve Kleiboeker as they delve into the company's 40-year history. They share insights into the company’s founding, our evolution in the diagnostics landscape, the challenges we’ve overcome, the pivotal moments that have defined our path in the field of diagnostics, and the innovative spirit that drives our commitment to precision medicine. Listeners will gain a deeper understanding of the milestones that have shaped the organization and our ongoing goal to advance patient care through cutting-edge technology.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 1 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 2 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 3 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode we feature a recent White Paper and our CMV T Cell immunity panel. (See the featured resource following. This episode discusses CMV cell mediated immunity and the recently released white paper evaluating various methodologies, including Eurofins Viracor’s CMV T Cell Immunity Panel.